Eisai (OTCMKTS:ESALY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday.
According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “
Eisai (ESALY) traded up $0.10 during midday trading on Monday, hitting $58.45. The company’s stock had a trading volume of 1,528 shares, compared to its average volume of 3,936. Eisai has a 1 year low of $50.31 and a 1 year high of $63.06. The company has a market cap of $17,304.69, a price-to-earnings ratio of 60.89 and a beta of -0.25. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.18 and a quick ratio of 1.81.
Eisai Co, Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company’s businesses include pharmaceutical business and other business. The Company’s segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.